dc.contributor.author |
Reynisson, Johannes |
en |
dc.contributor.author |
Court, Wendy |
en |
dc.contributor.author |
O'Neill, Chelsey |
en |
dc.contributor.author |
Day, J |
en |
dc.contributor.author |
Patterson, L |
en |
dc.contributor.author |
McDonald, E |
en |
dc.contributor.author |
Workman, Peter |
en |
dc.contributor.author |
Katan, M |
en |
dc.contributor.author |
Eccles, Sara |
en |
dc.date.accessioned |
2012-03-14T00:21:14Z |
en |
dc.date.issued |
2009-04-15 |
en |
dc.identifier.citation |
BIOORGANIC & MEDICINAL CHEMISTRY 17(8):3169-3176 15 Apr 2009 |
en |
dc.identifier.issn |
0968-0896 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/14285 |
en |
dc.description.abstract |
Phospholipase C-gamma (PLC-gamma) has been identi. ed as a possible biological target for anticancer drug therapy but suitable inhibitors are lacking. Therefore, in order to identify active compounds ( hits) virtual high throughput screening was performed. The crystal structure of the PLC-delta isoform was used as a model docking scaffold since no crystallographic data are available on its c counterpart. A pilot screen was performed using similar to 9.2 x 10(4) compounds, where the robustness of the methodology was tested. This was followed by the main screening effort where similar to 4.4 x 10(5) compounds were used. In both cases, plausible compounds were identi. ed ( virtual hits) and a selection of these was experimentally tested. The most potent compounds were in the single digit micro- molar range as determined from the biochemical (Flashplate) assay. This translated into similar to 15 mu M in a functional assay in cells. About 30% of the virtual hits showed activity against PLC-gamma (IC50 < 50 mu M). (C) 2009 Elsevier Ltd. All rights reserved. |
en |
dc.language |
EN |
en |
dc.publisher |
Elsevier |
en |
dc.relation.ispartofseries |
Bioorganic & Medicinal Chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0968-0896/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Virtual screening |
en |
dc.subject |
PLC-protein |
en |
dc.subject |
Oncology |
en |
dc.subject |
Docking |
en |
dc.subject |
Drug discovery |
en |
dc.subject |
PHOSPHOLIPASE-C-GAMMA |
en |
dc.subject |
SMALL-MOLECULE INHIBITORS |
en |
dc.subject |
COMPOUND LIBRARIES |
en |
dc.subject |
TUMOR PROGRESSION |
en |
dc.subject |
SCORING FUNCTIONS |
en |
dc.subject |
BINDING-AFFINITY |
en |
dc.subject |
ESCHERICHIA-COLI |
en |
dc.subject |
DRUG SOLUBILITY |
en |
dc.subject |
CELL MOTILITY |
en |
dc.subject |
DOCKING |
en |
dc.title |
The identification of novel PLC-gamma inhibitors using virtual high throughput screening |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.bmc.2009.02.049 |
en |
pubs.issue |
8 |
en |
pubs.begin-page |
3169 |
en |
pubs.volume |
17 |
en |
dc.rights.holder |
Copyright: Elsevier |
en |
dc.identifier.pmid |
19303309 |
en |
pubs.end-page |
3176 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
93792 |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
19303309 |
en |